↓ Skip to main content

Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse

Overview of attention for article published in Arthritis Research & Therapy, June 2017
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (61st percentile)

Mentioned by

twitter
4 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
31 Dimensions

Readers on

mendeley
34 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse
Published in
Arthritis Research & Therapy, June 2017
DOI 10.1186/s13075-017-1321-1
Pubmed ID
Authors

Matthew David Morgan, Matthew Szeto, Michael Walsh, David Jayne, Kerstin Westman, Niels Rasmussen, Thomas F. Hiemstra, Oliver Flossmann, Annelies Berden, Peter Höglund, Lorraine Harper

Abstract

Relapse of disease is frequent in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). It is unclear whether persistent ANCA when starting maintenance therapy increases the risk of relapse. We examined the association between ANCA status and relapse in two randomised controlled trials. ANCA-positive patients in two trials, CYCLOPS and IMPROVE, were switched from cyclophosphamide to maintenance therapy after achieving clinical remission. We classified patients as being either ANCA-positive or ANCA-negative at the time they started maintenance therapy. We compared the risk of relapse in ANCA-positive and ANCA-negative patients. Of 252 patients included, 102 (40%) experienced at least one relapse during the follow-up period. At the time of the switch from induction to maintenance therapy, 111 were ANCA-positive, of whom 55 (50%) relapsed, compared to 141 patients who were ANCA-negative, of whom 47 (33%) relapsed. In multivariable time-to-event analysis, a reduced risk of relapse was associated with having become ANCA-negative at the time of switching to maintenance therapy (hazard ratio 0.63, 95% confidence interval 0.42-0.95; p = 0.026). In addition, initial proteinase 3 (PR3)-ANCA, younger age, lower serum creatinine, pulsed cyclophosphamide for remission induction, and mycophenolate mofetil for remission maintenance were all associated with an increased risk of relapse. Becoming ANCA-negative before the switch to maintenance is associated with a reduced risk of relapse. CYCLOPS: ClinicalTrials.gov, NCT00430105 . Registered retrospectively on 31 January 2007. ClinicalTrials.gov, NCT00307645 . Registered retrospectively on 27 March 2006.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 34 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 15%
Student > Bachelor 4 12%
Researcher 4 12%
Professor 4 12%
Professor > Associate Professor 3 9%
Other 6 18%
Unknown 8 24%
Readers by discipline Count As %
Medicine and Dentistry 19 56%
Nursing and Health Professions 2 6%
Biochemistry, Genetics and Molecular Biology 1 3%
Immunology and Microbiology 1 3%
Agricultural and Biological Sciences 1 3%
Other 2 6%
Unknown 8 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 July 2017.
All research outputs
#6,378,201
of 12,476,200 outputs
Outputs from Arthritis Research & Therapy
#1,113
of 2,051 outputs
Outputs of similar age
#99,992
of 265,879 outputs
Outputs of similar age from Arthritis Research & Therapy
#1
of 2 outputs
Altmetric has tracked 12,476,200 research outputs across all sources so far. This one is in the 48th percentile – i.e., 48% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,051 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 45th percentile – i.e., 45% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,879 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them